Reduced pressure changes the conditions enough for frozen water to leave as vapor through sublimation rather than pass through a liquid state. This phase transition helps remove ice while the material remains frozen. In bioengineering, this distinction matters because preserving the frozen matrix can support retention of structure and stability during drying.
The phases remove different forms of water. During primary drying, ice undergoes sublimation under reduced pressure; secondary drying then removes moisture that remains bound to the material. Separating these functions allows the process to address both frozen water and residual moisture, supporting a final product intended for storage and later rehydration.
A porous dried matrix is important because it creates a product that can be rehydrated after storage. The structure also reflects the preservation goal: remove water without losing the material’s organization. For bioengineered proteins, cells, enzymes, vaccines, biomaterials, and formulations, this outcome can support handling and subsequent use.
Liquid conditions can promote degradation for some biological products, whereas drying reduces the water present during storage. The resulting solid form can extend shelf life and simplify transport, making the approach useful when proteins, vaccines, enzymes, cells, biomaterials, or pharmaceutical formulations need greater storage stability.
Applications include proteins, vaccines, enzymes, cells, biomaterials, and pharmaceutical formulations. These materials may be vulnerable to degradation while stored in liquid conditions, so converting them into a dry product can support longer storage and easier transport. The method therefore applies across biological materials and engineered formulations rather than to one product class.
It contributes by producing a dry, porous material that can be stored and later rehydrated. This combination can extend shelf life, simplify transport, and help maintain structure and stability. In bioengineering, those outcomes support the development of stable products ranging from biological reagents and vaccines to biomaterials and pharmaceutical formulations.